| 1.88 -0.09 (-4.57%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.34 |
1-year : | 2.62 |
| Resists | First : | 2 |
Second : | 2.25 |
| Pivot price | 1.82 |
|||
| Supports | First : | 1.61 |
Second : | 1.33 |
| MAs | MA(5) : | 1.81 |
MA(20) : | 1.89 |
| MA(100) : | 2.15 |
MA(250) : | 1.72 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 59.6 |
D(3) : | 38.4 |
| RSI | RSI(14): 48.6 |
|||
| 52-week | High : | 4.46 | Low : | 0.98 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ALLO ] has closed below upper band by 32.0%. Bollinger Bands are 48.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2 - 2.01 | 2.01 - 2.02 |
| Low: | 1.84 - 1.85 | 1.85 - 1.86 |
| Close: | 1.86 - 1.88 | 1.88 - 1.9 |
Allogene Therapeutics, Inc. operates as a clinical-stage immuno-oncology firm dedicated to the creation and commercialization of genetically engineered allogeneic T-cell therapies for the treatment of various cancers. A pivotal product in their development pipeline is UCART19, an allogeneic chimeric antigen receptor (CAR) T-cell therapy. This candidate is being developed, manufactured, and prepared for market release to address relapsed/refractory (R/R) CD19-positive B-cell acute lymphoblastic leukemia (ALL) in both children and adults. The company's portfolio also encompasses ALLO-501, an anti-CD19 allogeneic CAR T-cell candidate currently in Phase I clinical trials for R/R non-Hodgkin lymphoma. A related therapeutic, ALLO-501A, is progressing through Phase I/II studies, targeting R/R large B-cell lymphoma or transformed follicular lymphoma. Furthermore, Allogene is advancing several other promising candidates: ALLO-715, an allogeneic CAR T-cell therapy in Phase I for R/R multiple myeloma; ALLO-605, another allogeneic CAR T-cell designed for multiple myeloma; and ALLO-647, an anti-CD52 monoclonal antibody. Their investigational therapies also include those targeting CD70 for renal cell cancer, ALLO-819 (an allogeneic CAR T-cell treatment) for acute myeloid leukemia, and DLL3 for small cell lung cancer and other aggressive neuroendocrine tumors. Allogene maintains a robust network of strategic alliances, which includes licensing and collaboration agreements with organizations such as Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. They also hold a clinical trial collaboration with SpringWorks Therapeutics, Inc. Additionally, a strategic partnership with The University of Texas MD Anderson Cancer Center supports the preclinical and clinical evaluation of their allogeneic CAR T-cell product pipeline. Founded in 2017, the company's corporate headquarters are located in South San Francisco, California.
Wed, 29 Jul 2026
Allogene Therapeutics (ALLO) Stock Gains on FDA RMAT and Fast Tr - GuruFocus
Wed, 29 Jul 2026
Insider Sellers Might Regret Selling Allogene Therapeutics Shares at a Lower Price Than Current Market Value - simplywall.st
Wed, 29 Jul 2026
Allogene Therapeutics' Cemacabtagene Ansegedleucel Receives FDA RMAT, Fast Track Designations - marketscreener.com
Wed, 29 Jul 2026
Allogene Therapeutics stock rises on FDA regulatory designations - Investing.com
Wed, 29 Jul 2026
Allogene Therapeutics (ALLO) Gains FDA RMAT and Fast Track Desig - GuruFocus
Wed, 29 Jul 2026
Allogene Reports No Minimal Residual Disease in 7 of 12 Cema-Cel Patients - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 345 (M) |
| Shares Float | 271 (M) |
| Held by Insiders | 11 (%) |
| Held by Institutions | 53.9 (%) |
| Shares Short | 59,710 (K) |
| Shares Short P.Month | 48,040 (K) |
| EPS | -0.77 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.13 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26 % |
| Return on Equity (ttm) | -52.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.39 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -109 (M) |
| Levered Free Cash Flow | -70 (M) |
| PE Ratio | -2.45 |
| PEG Ratio | 0 |
| Price to Book value | 1.64 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|